- Home
- JBSS vs MYGN Comparison
JBSS vs MYGN Comparison
Compare JBSS & MYGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- JBSS
- MYGN
- Stock Information
- Founded
- JBSS 1959
- MYGN 1991
- Country
- JBSS United States
- MYGN United States
- Employees
- JBSS N/A
- MYGN N/A
- Industry
- JBSS Specialty Foods
- MYGN Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Sector
- JBSS Consumer Staples
- MYGN Health Care
- Exchange
- JBSS Nasdaq
- MYGN Nasdaq
- Market Cap
- JBSS 794.3M
- MYGN 744.7M
- IPO Year
- JBSS 1991
- MYGN 1995
- Fundamental
- Price
- JBSS $63.18
- MYGN $4.92
- Analyst Decision
- JBSS
- MYGN Hold
- Analyst Count
- JBSS 0
- MYGN 15
- Target Price
- JBSS N/A
- MYGN $15.14
- AVG Volume (30 Days)
- JBSS 61.9K
- MYGN 2.1M
- Earning Date
- JBSS 08-19-2025
- MYGN 08-05-2025
- Dividend Yield
- JBSS 3.34%
- MYGN N/A
- EPS Growth
- JBSS N/A
- MYGN N/A
- EPS
- JBSS 4.72
- MYGN N/A
- Revenue
- JBSS $1,107,742,000.00
- MYGN $831,300,000.00
- Revenue This Year
- JBSS N/A
- MYGN N/A
- Revenue Next Year
- JBSS N/A
- MYGN $6.68
- P/E Ratio
- JBSS $13.28
- MYGN N/A
- Revenue Growth
- JBSS 7.40
- MYGN 7.38
- 52 Week Low
- JBSS $58.47
- MYGN $3.81
- 52 Week High
- JBSS $105.63
- MYGN $29.30
- Technical
- Relative Strength Index (RSI)
- JBSS 51.18
- MYGN 46.03
- Support Level
- JBSS $62.07
- MYGN $4.78
- Resistance Level
- JBSS $65.73
- MYGN $5.29
- Average True Range (ATR)
- JBSS 1.38
- MYGN 0.32
- MACD
- JBSS 0.17
- MYGN 0.11
- Stochastic Oscillator
- JBSS 49.30
- MYGN 60.98
About JBSS John B. Sanfilippo & Son Inc.
John B Sanfilippo & Son Inc is one of the processors and distributors of peanuts, pecans, cashews, walnuts, almonds, and other nuts in the United States. These nuts are sold under a variety of private brands and the Fisher, Orchard Valley Harvest, and Sunshine Country brand names. It also markets and distributes, and in the majority of cases, manufactures or processes, a diverse product line of food and snack products, including peanut butter, almond butter, cashew butter, candy and confections, snacks and trail mixes, snack bites, sunflower kernels, dried fruit, corn snacks, sesame sticks and other sesame snack products under private brands and brand names.
About MYGN Myriad Genetics Inc.
Myriad Genetics Inc is a molecular diagnostics company that provides testing services designed to assess an individual's risk of developing a disease. The firm produces MyRisk, a 48-gene panel capable of identifying the elevated risk of developing 11 types of cancer. Other diagnostic products include BRACAnalysis CDx, the FDA-approved companion diagnostic for PARP inhibitors; GeneSight, which helps improve responses to psychotropic drugs for patients suffering from depression; and Prequel, a noninvasive prenatal test. Precise Oncology Solutions, launched in 2022, combines Precise Tumor with companion diagnostic and prognostic tests such as MyChoice CDx, Prolaris, and EndoPredict. The firm also offers pharma and biotech companies biomarker discovery and companion diagnostic services.